Llwytho...

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis

Alemtuzumab is the newest disease-modifying therapy approved for the treatment of relapsing multiple sclerosis. Alemtuzumab is an anti-CD52 targeted antibody that causes lysis of T and B lymphocytes, monocytes, natural killer cells, macrophages, and dendritic cells. Following its administration, a p...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuropsychiatr Dis Treat
Prif Awduron: Babij, Rachel, Perumal, Jai S
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2015
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4445870/
https://ncbi.nlm.nih.gov/pubmed/26056453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S60518
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!